VanEck Pharmaceutical ETF
PPH
47 hedge funds and large institutions have $94.5M invested in VanEck Pharmaceutical ETF in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 5 closing their positions.
64% more capital invested
Capital invested by funds: $57.7M → $94.5M (+$36.7M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
7.82% more ownership
Funds ownership: 32.75% → 40.57% (+7.8%)
7% more funds holding
Funds holding: 44 → 47 (+3)
17% less call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.62M
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
+$41.6M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.26M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$804K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$672K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$5.74M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.46M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.14M |
| 4 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$423K |
| 5 |
DI
DFPG Investments
Sandy,
Utah
|
-$287K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AP
51
Advisors Preferred
Rockville,
Maryland
| – | -$15K | -269 | Closed |
|
52
William Blair & Company
Chicago,
Illinois
| – | -$5K | -90 | Closed |
|
PPH Hedge Fund Activity: Q2 2020 in Review
47 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2020, worth a combined $94.5M — up 64% from $57.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PPH positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 14 trimmed.
The largest buyer was Mivtachim The Workers Social Insurance Fund, opening a new position worth an estimated $41.6M. The largest seller was Orion Portfolio Solutions, cutting an estimated $5.74M.
- 47 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2020, up from 44 in Q1 2020.
- Funds reported $94.5M of VanEck Pharmaceutical ETF stock for Q2 2020, up 64% quarter-over-quarter.
- 8 funds opened new VanEck Pharmaceutical ETF positions in Q2 2020 and 5 closed out, a net change of +3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2020 was Mivtachim The Workers Social Insurance Fund, an estimated $41.6M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2020 was Orion Portfolio Solutions, an estimated $5.74M sold.
Based on aggregated 13F filings for Q2 2020.